Dengue, Chikungunya and Zika are the vector-borne diseases that constitute a potential epidemiological risk due to the recent increase in cases, complications, and severity. The co-circulation of the three diseases is a matter of public health interest due to their transmission by the same vector as well as the increase in the number of cases of severe dengue hemorrhagic fever, post-chikungunya chronic joint disease and microcephaly related to Zika virus. Therefore, it is important to be familiar with the various clinical presentations and laboratory methods to make the differential diagnosis, start appropriate treatment, and prevent the associated complications.
licensed Dengue, Chikungunya and Zika vaccine available and the only means of prevention is through surveillance and vector control. There is also no effective anti-viral therapeutic on the market and supportive therapy such as fluid replacement is the only treatment for severe forms of the disease. Therefore, an early and accurate laboratory diagnosis of flaviviruses could assist in clinical management. 11 Disease Overview: All three viruses are mainly transmitted by the same vectors, Aedes aegypti and Aedes albopictus. 12 Infections with these viruses are often asymptomatic; the initial clinical presentation is non-specific and symptoms such as fever, maculopapular rash, musculoskeletal pain, headache and conjunctivitis can be seen with any of these viruses. 13 Although in most cases the disease is mild but they have been linked to complications such as ZIKV infection with congenital malformations, in particular microcephaly, and neurological condition, Guillain-Barré syndrome. 14 CHIKV can result in a severe chronic arthralgia and/ or arthritis that can last months to years following the initial infection. 15, 16 In a small proportion of cases, DENV infections develop into the life-threatening dengue hemorrhagic fever or dengue shock syndrome. 17
Diagnostic Methods:
Assay selection depends both on the timing of sample collection and the purpose of testing. In the acute phase of infection, assays that detect the virus directly by viral isolation, viral RNA or viral antigen perform best. In the convalescent phase of infection, serological assays that detect the host antibody response (IgM, IgG and IgA antibodies) can be used, though paired acute and convalescent samples are used to diagnose/ distinguish current from past infections. 18 The laboratory diagnosis for arboviruses has long relied on serological methods which can be challenging. 19, 20 Neutralization assays are useful but cannot always yield a definitive diagnosis. 21 However, if blood and urine samples are obtained early in the illness, a firm diagnosis can be established by specific detection using molecular methods. 22
(1) Virus Isolation:
Virus isolation is very labor-intensive and costly but is more specific than antibody detection using serologic methods. 23 Viral culture may detect virus in the first 3 days of illness; however, it should be handled under biosafety level (BSL) 3 conditions. 24 Isolation of DENV or CHIKV can be performed via mosquito inoculation or cell culture method. Mosquito inoculation is the most sensitive isolation method but is impractical for routine diagnosis due to the highly specialized requirements and high maintenance costs. 25 CHIKV isolation can also be performed by intracerebral inoculation of mice. 26 Cell culture is in wider use, with preference given to the mosquito cell line C6/36 (cloned from A. albopictus) or AP61 (cloned from A. pseudoscutellaris). 23, 26 Other less sensitive options include mammalian cell cultures such as Vero, LLC-MK2, and BHK-21. The resultant virus isolate may be further characterized by subsequent in vitro studies, such as genome sequencing, virus neutralization, and infection studies. 25 Virus isolation is highly specific and has a theoretical detection limit of a single viable virus, although, in practice, the sensitivity is only approximately 40.5% in cell line-based virus isolation. It also requires highly trained operators, a dependence on sample integrity. A short viremia period from illness onset provides a narrow window of opportunity for diagnosis by culture. Virus isolation followed by an immunofluorescence assay for confirmation requires days to weeks. Therefore, despite its advantages, this approach is not widely used in routine diagnostic laboratories and may be of more use in surveillance purposes. 23, 26 There are reports describing the Zika infection of various primary cells or immortalized cell lines. Moreover, ZIKV was shown to replicate in various human cell types like skin cells and lung epithelial cells. The Aedes C6/36 cells were also infected, this was also described for other related viruses. (2) Nucleic acid detection: Detection of viral nucleic acid can be accomplished by reverse transcriptase polymerase chain reaction (RT-PCR) or isothermal amplification methods.
Polymerase chain reaction (RT-PCR)
Virus nucleic acid detection by RT-PCR is only effective during the viraemic phase i.e., within the first week of clinical symptoms onset. 28 There is a wide variety of specimen types that can be tested with RT-PCR. Serum and/or plasma can be used for diagnosis of DENV, CHIKV and ZIKV. For DENV, urine and saliva have been found to be suitable specimen types as well. 29 It has also been shown that for detection of Zika virus urine can be the ideal sample type. 30 Dengue fever can be diagnosed by direct detection of dengue virus, e.g. by PCR only during the viraemic phase of dengue infection when initial symptoms arise (approx. 0 to 5 days after onset of symptoms). 31 Current tests are between 80-90% sensitive, and more that 95% specific. PCR can be used to determine which of the 4 serotypes dengue is causing the infection. 32 Chikungunya infections cause high levels of viremia which typically last for 4-6 days after the onset of illness. 33 RT-PCR can therefore be done within the first 7 days from an acute-phase specimen to confirm chikungunya virus infection. 34 The sensitivity for CHIKV in the early stages of infection is 88.3%. 24 RT-PCR products may also be used for genotyping of the virus, allowing comparisons with virus samples from various geographical sources. 35 In case of Zika this is the test of choice due to its high sensitivity and specificity, which in some studies are as high as 100% for both. In areas of active Zika virus transmission, the Centers for Disease Control and Prevention (CDC) guidelines propose that pregnant women with Zika symptoms should be analysed with RT-PCR. If the results are positive or inconclusive, repeated foetal ultrasounds and PCR in amniotic fluid must be performed throughout the pregnancy. If the results are negative, an ultrasound must be performed to look for microcephaly or intracranial calcifications. 36, 37 In response to the diagnostic challenges presented by these viruses, the CDC developed the Trioplex realtime reverse transcriptase-polymerase chain reaction assay (Trioplex assay) for the concurrent detection of DENV, CHIKV and ZIKV RNA in human serum, plasma and cerebrospinal fluid (CSF). 38 Simultaneous testing of more than one specimen type from each patient provides a 6.4% additional diagnostic sensitivity. 39 
Isothermal amplification method:
Reverse transcription-loop mediated isothermal amplification (RT-LAMP) has emerged for viral detection due to simplified thermal management and high sensitivity and specificity towards targeted sequences. 40 [41] [42] [43] (3) Viral antigen detection: Nonstructural protein 1 (NS1) antigen is a highly conserved glycoprotein produced during the virus replication process. The NS1 glycoprotein is produced by all flaviviruses. 44, 45 Several commercial assays, consisting of both rapid tests and enzyme-linked immunosorbent assay (ELISA) kits, are available for the detection of the NS1 antigen. Kumar et al. and Chakraverti et al. found no significant difference in sensitivity and specificity between ICT and ELISA tests for detection of dengue infection. 46, 47 Serum is the most common sample type. In DENV infections the Dengue Virus NS1 ELISA is an important early screening test, which is possible from day 1 to approximately day 18 after onset of symptoms that helps to minimize the diagnostic gap between RT-PCR and antibody positivity. 24 This technique reportedly has a sensitivity of 80-100% and a specificity of 100%. An antigenbased commercial detection assay is not widely available for CHIKV, ZIKV. The ones described by Chen et al. and Bosch et al. could not gain popularity as the test performance was poor. 48, 49 (4) Serological diagnosis:
Serological tests provide a much longer window for diagnostics than direct detection methods.
Antibody detection:
Antibodies against DENV, CHIKV and ZIKV appear around 4 to 7 days after symptom onset. 50 The immune response varies depending on whether the individual has a primary or secondary flavivirus infection. 24 Antibody response to infection differs according to the immune status of the host. 10 When flavivirus infection occurs in persons who have not previously been infected with a flavivirus or immunized with a flavivirus vaccine (e.g. for yellow fever, Japanese encephalitis, tick-borne encephalitis), the patients develop a primary antibody response characterized by a slow increase of specific antibodies. IgM antibodies are the first immunoglobulin isotype to appear. These antibodies are detectable in 50% of patients by day 3 of illness, increasing to 80% by day 5 and 99% by day 10. 23 IgM levels peak about two weeks after the onset of symptoms and then decline generally to undetectable levels over 2-3 months. IgG is generally detectable at low titres at the end of the first week of illness, increasing slowly thereafter, with serum IgG still detectable after several months, and probably even for life. 25, 51 During a secondary infection, antibody titres rise rapidly and react broadly against many flaviviruses. The dominant immunoglobulin isotype is IgG which is detectable at high levels, even in the acute phase, and persists for periods lasting from 10 months to life. Early convalescent stage IgM levels are significantly lower in secondary infections than in primary ones and may be undetectable in some cases, depending on the test used. 52 The following table summarizes results that may be seen with antibody testing.
There are several commercial assays available for the detection of the flavivirus antibody consisting of Immunochromatographic test (ICT), Enzyme-linked immunosorbent assay (ELISA), Immunofluorescence tests, Haemagglutination tests.
4.1.1: Immunochromatographic test (ICT):
Relatively inexpensive serological tests, and in particular rapid point-of-care device, have become more widely used in endemic settings. Although not as sensitive as PCR or ELISA, ICT is quick and require only a minimum of technical expertise to perform. 11 ICT for IgM and IgG are routinely used in clinical laboratories for the rapid diagnosis of dengue and can differentiate between primary and secondary infections. Rapid CHIKV IgM tests are now available, but little information exists regarding their performance. The sensitivity of these tests evaluated by Burdino et al. in settings with a high prevalence of CHIKV infection is poor (range 1.9%-50.8%) compared with that for reference assays, especially in the acute phase of disease. 53 Recently, Rapid Diagnostic Test (RDT) kit for detecting IgG/IgM antibodies against Zika virus (Zika IgG/IgM RDT kit) has been developed by Kim et al. and proved to be effective in the field. The diagnostic accuracy of Zika RDT was fairly high; sensitivity and specificity for IgG was 99.0 and 99.3%, respectively, while for IgM it was 96.7 and 98.7%, respectively. The Zika RDT kit is very simple to use, rapid to assay, and very sensitive and highly specific. Therefore, it would serve as a choice of method for point-of-care diagnosis and large scale surveys of ZIKV infection among people under clinical or field conditions worldwide in endemic areas. 54
4.1.2: Enzyme-linked immunosorbent assay (ELISA):
MAC-ELISA has become an important tool for routine diagnosis. Different formats such as capture ELISA, capture ultramicro ELISA, dot-ELISA, AuBioDOT IgM capture and dipsticks have been developed. MAC-ELISA has a sensitivity and specificity of approximately 90% and 98%, respectively but only when used five or more days after onset of fever (i.e., in convalescent phase). 24 Detection of anti-dengue IgM antibodies (MAC-ELISA) is the serological test of choice. It is not possible to detect serotypes of the virus with these tests. 55 CHIKV IgM can be detected by CHIKV IgM antibody capture enzyme-linked immunosorbent assays (MAC-ELISAs). 56 Detection of IgM through the ELISA technique may be used for CHIKV from 4 days after the onset of fever to 2 months. A sensitivity of 81.8% was reported by Chen et al. for late stages of the disease. IgG may be detected in samples in the convalescence stage and persist throughout life. 43 To diagnose ZIKV, detection of IgM by ELISA may be used in the convalescence phase (after 6 days after onset of symptoms). 24 Zika virus-specific IgM levels are variable, but generally are positive starting near day 4 after onset of symptoms and continuing for up to 12 weeks post symptom onset or exposure, but may persist longer. For non-pregnant symptomatic individuals with possible exposure to Zika virus, nucleic acid testing (NAT) in serum and urine and Zika virus and/or dengue virus IgM testing of serum should be performed. Zika virus and dengue virus IgM serology testing should be performed on NAT negative samples collected <14 days after onset of symptoms or on samples collected e"14 days after onset of symptoms. NAT testing is not recommended on specimens collected e" 14 days after symptom onset. For zika virus infected symptomatic pregnant women, IgM serology is performed concurrently with NAT as soon as possible, up to 12 weeks after symptom onset. IgM serology testing is not routinely recommended for asymptomatic pregnant women with ongoing possible Zika virus exposure (i.e., residence in or frequent travel to an area with risk of Zika). Here, NAT testing is recommended three times during pregnancy. Asymptomatic pregnant women with recent possible exposure to Zika virus but no ongoing exposure (i.e., travelers) may be considered for testing. Although testing is not routinely recommended, but if testing is performed, the same algorithm as for symptomatic pregnant women should be followed using the timeframe from the last possible exposure to Zika virus. 57 Serological methods are useful for studying the longterm consequences of infection. For example, if the link between ZIKV infection and congenital malformations is confirmed, ZIKV serology could play an important future role in prenatal diagnostics. 58 Serology is also useful for screening donated blood, especially in travelers returning from DENV, CHIKV and ZIKV endemic regions to non affected countries. 23 A further, critical role for serological studies is to monitor the growing epidemiological reach of flavivirus. 60, 61 This approach is not used very often and requires additional evaluation.
4.1.3: Immunofluorescence assays:
Immunofluorescence assays are sensitive and specific but lack the ability to quantify antibodies, are thus subjective. Antibody detection by indirect immunofluorescence test (IIFT) is based on cells infected with the corresponding virus, which provide highly sensitive diagnostics. Positive and negative results are evaluated by fluorescence microscopy. 62 In clinically characterized samples the IIFT also had high performance (96% accuracy), but a technician skilled in immunofluorescence assay techniques is required. 57
4.1.4: Haemagglutination-inhibition tests:
Clinical symptoms along with a fourfold Haemagglutination Inhibition (HI) antibody difference in paired serum samples indicate flavivirus infection. 63 The assay does not discriminate between infections by closely related flaviviruses (e.g. between dengue virus and Japanese encephalitis virus or West Nile virus) nor between immunoglobulin isotypes. The response to a primary infection is characterized by the low level of antibodies in the acute-phase serum drawn before day 5 and a slow elevation of HI antibody titre thereafter. During secondary dengue infections HI antibody titre rises rapidly, usually exceeding 1:1280. Values below this are generally observed in convalescent sera from patients with primary responses. 23
(5) Plaque reduction neutralization tests (PRNT):
Plaque reduction neutralization tests (PRNT) are very useful because they are quite specific and gold standard for confirmation of serologic test results. Plaque reduction neutralization test may help in determining false positive IgM results. Almost 90% samples are positive by plaque reduction neutralization test out of all MAC-ELISA positive cases. A sample with positive or equivocal MAC-ELISA results with a neutralizing titer is classified as a confirmed virus positive sample; those with negative results of plaque reduction neutralization testing are considered to have nonspecific reactivity (i.e., to be negative for virus). 57 Due to cross-reaction with other flaviviruses and possible nonspecific reactivity, results of MAC-ELISA may be difficult to interpret. Consequently, presumed positive, equivocal, or inconclusive tests must be forwarded for confirmation by plaque-reduction neutralization testing (PRNT). 58 The major drawback to PRNT is that it requires the use of live virus. The test must be carried out in BSL-3 that requires special laboratory containment equipments. 63
(6) Matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS):
Matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has emerged as a potential tool for microbial identification and diagnosis. The process is rapid, sensitive, and economical in terms of both labor and costs involved. The limitation of the technology is that identification of new isolates is possible only if the spectral database contains peptide mass fingerprints of the type strains of specific genera/species/subspecies/strains. 64 Among these three viruses, only Type 1 dengue virus can be detected by MALDI-TOF MS revealed by a study performed by Chen et al. 65 Molecular testing 1 (<7 days after symptom onset) 
RT

Figure-1. Tiered algorithm for arbovirus detection for suspected causes of Dengue Chikungunya or Zika (only performed if patient symptomatic and travel history indicates travel to affected area) 66
1 Due to extensive cross-reactivity in flavivirus serological assays, for samples collected <7 days of illness onset, molecular detection should be performed first. 2 Perform if samples >4 days after symptom onset. 3 Extensive cross-reactivity would be expected in samples from DENV/ZIKV circulation areas. A positive IgM assay with either antigen should be confirmed by using PRNT against ZIKV and DENV as well as any other flavivirus that might be found in that geographic area (including travel areas). 4 PRNT should include any flavivirus that might be found in that geographic area (including travel areas).
The Laboratory diagnosis Dengue, Chikungunya and Zika is challenging, as well as confusing. The gold standard for diagnosis of Dengue, Chikungunya and Zika in a febrile patient is obviously the specific virus detection, virus isolation and virus identification after by cell culture. However, this is gradually being replaced by real time reverse transcriptase polymerase chain reaction (RT-PCR) method for more rapid diagnosis. 67 However, the tests are almost impractical in most places because of requirement of specialized laboratory facilities and are also laborious. They are feasible only in rare centers of national importance, and hence in most or almost all laboratory serological methods are being performed. 68 Serological diagnosis is a most challenging matter due to its cross-reactivity to homologous and heterologous flavivirus antigens. However, great advances are achieved in analyzing the methods that target different structural and nonstructural proteins for serodiagnosis. Of these, the NS1, IgM, IgG detection by ICT and ELISA is the most favored one because of the ease and rapidity of the test. Thus, while the Rapid test can be more feasible in small peripheral laboratories and in field situations, in wellestablished laboratories, the concomitant performance of the Rapid test, with confirmation by the ELISA on those samples, ensures both rapidity as well as quality of reported results. 67 Whichever the test, the complexity 
Conclusion:
A range of laboratory diagnostic methods has been developed to support patient management and disease control. The choice of diagnostic method depends on the purpose for which the testing is done (e.g. clinical diagnosis, epidemiological survey, and vaccine development), the type of laboratory facilities and technical expertise available, costs, and the time of sample collection. In general, tests with high sensitivity and specificity require more complex technologies and technical expertise, while rapid tests may compromise sensitivity and specificity for the ease of performance and speed. New diagnostic methods continue to be innovated, such as micro fluidics, paper-based diagnostics, chip-based systems, micro and nanofabrication technologies, deep sequencing, among others. Despite advances in diagnostics for flaviviral infections, there is a critical need for more sensitive, specific, easy to use and affordable tests for point of care (POC) diagnosis, multiplex virologic and serologic assays to differentiate co-circulating significance (e.g, Dengue, Chikungunya, Zika and Yellow fever) and methods for viral quantification and genomic characterization.
